Document is current

Article History

Received: 6 April 2025

Accepted: 17 April 2025

First Online: 9 May 2025

Declarations

:

: The manuscript is based on trial protocol version 2, which was issued on 11 November 2024. The study protocol has been approved by the ethics committees at the three main sites: the Research Ethics Board, Institut universitaire en santé mentale de Québec, Québec, Canada, Toronto Metropolitan University Research Ethics Board, Toronto, Ontario, and the Royal Ottawa Health Care Group (ROHCG) Research Ethics Board, Ottawa, Ontario. Study coordinators will obtain written informed consent from all prospective participants at baseline.

: All authors have given their consent for publication.

: Dr. Morin reports receiving research grants from CIHR, NIH, Eisai, Idorsia, and Lallemand Health; serving on advisory boards for Eisai, Idorsia, and Haleon; and receiving royalties from Mapi Research Trust. Dr. Dang-Vu reports receiving research grants from CIHR, NSERC, Weston Family Foundation, Hypersomnia Foundation, Jazz Pharmaceuticals, and Paladin Labs; consulting fees from Eisai, Idorsia, and Jazz Pharmaceuticals; honoraria from Eisai and Jazz Pharmaceuticals; and serving on advisory boards for Eisai, Idorsia, and Hypersomnia Foundation. Dr. Robillard reports receiving research grants from CIHR, VAC, University of Ottawa Medical Research Funds, Ontario Early Researcher Awards, and Atlas institute for veterans and families; payment from Wellcome Foundation and Boehringer Ingelheim; serving as CO-Chair for Canadian Sleep Research Consortium and executive member for Canadian Sleep Society; and receiving In-Kind Contribution (EEG monitors) from Interaxon. The other co-authors declare that they have no competing interests.